In summary, we prepared ROS-responsive GA-conjugated DEAE-dextran nanoparticles (DGA) and demonstrated their neuroprotective ability by inhibiting HMGB1 and modulating microglia phenotypes to improve the therapeutic effect of stroke. This evidence concerns the gene HMGB1 and Stroke.